1. Home
  2. ANAB vs GILT Comparison

ANAB vs GILT Comparison

Compare ANAB & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$53.61

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Gilat Satellite Networks Ltd.

GILT

Gilat Satellite Networks Ltd.

HOLD

Current Price

$11.01

Market Cap

843.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
GILT
Founded
2005
1987
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
843.0M
IPO Year
2015
1997

Fundamental Metrics

Financial Performance
Metric
ANAB
GILT
Price
$53.61
$11.01
Analyst Decision
Buy
Strong Buy
Analyst Count
12
2
Target Price
$71.67
$19.00
AVG Volume (30 Days)
818.3K
553.3K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
91.02
N/A
EPS
N/A
N/A
Revenue
$234,603,000.00
N/A
Revenue This Year
N/A
$15.06
Revenue Next Year
$52.14
$11.72
P/E Ratio
N/A
$42.82
Revenue Growth
157.01
N/A
52 Week Low
$17.11
$7.22
52 Week High
$73.30
$20.99

Technical Indicators

Market Signals
Indicator
ANAB
GILT
Relative Strength Index (RSI) 44.82 37.62
Support Level $52.32 $10.42
Resistance Level $57.70 $13.82
Average True Range (ATR) 4.55 0.55
MACD -0.98 0.04
Stochastic Oscillator 24.72 18.58

Price Performance

Historical Comparison
ANAB
GILT

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.

Share on Social Networks: